Don’t worry, the FDA will stall this as long as possible to let one of O’Bambi’s fovorite companies become the only source.
posted on 03/31/2012 6:26:30 AM PDT
This is based on an interesting concept that has been around for awhile. Essentially this approach is based on a vaccination to induce an immune response to oxidized LDL cholesterol. The data in animals is good, but it obviously won't be clear that this will be therapeutic in patients until it is tested in clinical trials. I believe the company that is developing this is called CardioVax (U.S. based), but I'm not sure.
One thing that I'd be worried about is whether or not this approach could inadvertently induce deleterious immune responses.
FreeRepublic.com is powered by software copyright 2000-2008 John Robinson